Log In
Print this Print this

biosimilar erythropoietin, epoetin alfa (Binocrit) (HX575)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionBiosimilar version of erythropoietin (EPO)
Molecular Target Erythropoietin (EPO) receptor
Mechanism of ActionErythropoietin (EPO) receptor agonist; Biosimilar
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationAnemia
Indication DetailsTreat anemia in patients with chronic renal failure (CRF); Treat cancer chemotherapy-associated anemia; Treat cancer treatment-associated anemia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today